Synthetic Biologics Inc (NYSEAMERICAN:SYN) was down 4.3% on Monday . The company traded as low as $0.21 and last traded at $0.22. Approximately 530,700 shares were traded during trading, a decline of 29% from the average daily volume of 747,526 shares. The stock had previously closed at $0.23.
Several research firms have recently commented on SYN. Zacks Investment Research upgraded Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Wednesday, March 14th. Griffin Securities downgraded Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Wednesday, May 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Synthetic Biologics in a report on Friday, May 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $0.25.
Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings data on Tuesday, May 8th. The company reported ($0.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.03.
Several institutional investors and hedge funds have recently added to or reduced their stakes in SYN. Citadel Advisors LLC increased its holdings in Synthetic Biologics by 312.1% during the 4th quarter. Citadel Advisors LLC now owns 241,797 shares of the company’s stock valued at $122,000 after purchasing an additional 183,120 shares during the period. Virtu Financial LLC increased its holdings in Synthetic Biologics by 256.1% during the 4th quarter. Virtu Financial LLC now owns 299,577 shares of the company’s stock valued at $152,000 after purchasing an additional 215,440 shares during the period. Blair William & Co. IL increased its holdings in Synthetic Biologics by 14.8% during the 1st quarter. Blair William & Co. IL now owns 1,980,857 shares of the company’s stock valued at $631,000 after purchasing an additional 255,096 shares during the period. Finally, 683 Capital Management LLC purchased a new position in Synthetic Biologics during the 4th quarter valued at about $762,000.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.